EP3375291A1 - Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung - Google Patents

Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung Download PDF

Info

Publication number
EP3375291A1
EP3375291A1 EP17161671.7A EP17161671A EP3375291A1 EP 3375291 A1 EP3375291 A1 EP 3375291A1 EP 17161671 A EP17161671 A EP 17161671A EP 3375291 A1 EP3375291 A1 EP 3375291A1
Authority
EP
European Patent Office
Prior art keywords
lacto
acid
saccharide
aqueous solution
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17161671.7A
Other languages
English (en)
French (fr)
Other versions
EP3375291B1 (de
Inventor
Dr. Dirk Wartenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chr Hansen HMO GmbH
Original Assignee
Jennewein Biotechnologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58448315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3375291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jennewein Biotechnologie GmbH filed Critical Jennewein Biotechnologie GmbH
Priority to EP17161671.7A priority Critical patent/EP3375291B1/de
Priority to ES17161671T priority patent/ES2928859T3/es
Priority to DK17161671.7T priority patent/DK3375291T3/da
Priority to PL17161671.7T priority patent/PL3375291T3/pl
Priority to MX2019010872A priority patent/MX2019010872A/es
Priority to KR1020197023924A priority patent/KR20190130125A/ko
Priority to SG11201906991PA priority patent/SG11201906991PA/en
Priority to PCT/EP2018/056727 priority patent/WO2018167293A1/en
Priority to JP2019550677A priority patent/JP7186175B2/ja
Priority to CN201880018599.8A priority patent/CN110418577A/zh
Priority to RU2019131462A priority patent/RU2797427C2/ru
Priority to US16/493,996 priority patent/US20200087690A1/en
Priority to BR112019017840A priority patent/BR112019017840A8/pt
Priority to EP18710075.5A priority patent/EP3595455A1/de
Priority to AU2018235156A priority patent/AU2018235156B2/en
Publication of EP3375291A1 publication Critical patent/EP3375291A1/de
Priority to PH12019550151A priority patent/PH12019550151A1/en
Publication of EP3375291B1 publication Critical patent/EP3375291B1/de
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/12—Disaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C7/00—Other dairy technology
    • A23C7/04—Removing unwanted substances other than lactose or milk proteins from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
    • A23C9/1542—Acidified milk products containing thickening agents or acidified milk gels, e.g. acidified by fruit juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
    • A23C9/1565—Acidified milk products, e.g. milk flavoured with fruit juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/42—Preservation of non-alcoholic beverages
    • A23L2/46—Preservation of non-alcoholic beverages by heating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/68—Acidifying substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13B—PRODUCTION OF SUCROSE; APPARATUS SPECIALLY ADAPTED THEREFOR
    • C13B50/00—Sugar products, e.g. powdered, lump or liquid sugar; Working-up of sugar
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13B—PRODUCTION OF SUCROSE; APPARATUS SPECIALLY ADAPTED THEREFOR
    • C13B50/00—Sugar products, e.g. powdered, lump or liquid sugar; Working-up of sugar
    • C13B50/002—Addition of chemicals or other foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K13/00—Sugars not otherwise provided for in this class
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K13/00—Sugars not otherwise provided for in this class
    • C13K13/007—Separation of sugars provided for in subclass C13K
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K5/00—Lactose
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K7/00—Maltose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to methods involving a thermal treatment of an aqueous solution containing at least one reducing saccharide. More specifically, the invention relates to methods of preventing isomerization of the reducing saccharide in an aqueous solution upon a thermal treatment of aqueous solution containing the reducing saccharide.
  • Maintaining a sterile environment is often a prerequisite for cultivating cells in biotechnological production processes.
  • these processes are often prone to foreign growth by adventitious bacteria, fungi or viruses.
  • Being contaminated with adventitious microorganisms has a severe impact on the manufacturing process as it impairs productivity (decreased production capacity due to a degradation or modification of the raw materials, the desired product or the desired biomass, and extended shut down periods of the bioreactor for removal of the contaminant), product quality and product safety (through contaminations of the final product due to the foreign growth itself and/or due to metabolites produced by the undesired microorganisms).
  • Heat treatment of any heat-tolerant supplies is known to be the most reliable and effective sterilization method and wet heat is most widely used for achieving heat sterilization.
  • Wet heat (steam) sterilization means exposing the components to be sterilized to pressurized steam for some time.
  • Typical wet heat sterilization protocols that are used for sterilizing equipment and supplies subject them to high-pressure saturated steam at 115 °C to 140 °C for around 60 to 3 minutes. These sterilization protocols may vary depending on the bioburden and nature of the raw material, solution or surface to be sterilized.
  • lactose (4- O - ⁇ -D-galactopyranosyl-D-glucopyranose, CAS-number: 63-42-3)
  • lactulose (4- O - ⁇ -D-galactopyranosyl-D-fructofuranose, CAS-number: 4618-18-2)
  • This type of isomerization is favored by basic pH and is also known as the Lobry de Bruyn-Alberda van Ekenstein transformation.
  • lactose is typically used as initial acceptor molecule for further glycosylatlon steps leading to the desired HMO to be produced.
  • the lactose being supplied has to be sterilized.
  • lactulose within the fermentation broth has to be avoided since it is a known laxative that should not be present in infant formula or any other nutritional product being supplemented with said HMOs. Furthermore, lactulose might be used by the HMO producing bacteria as an alternative acceptor molecule, thus, leading to oligosaccharides which are not present in nature.
  • the object has been achieved by a method wherein an acidic pH of a lactose solution is adjusted prior to and/or in the course of exposing the lactose solution to heat, notwithstanding that the principle of acidifying a sugar solution prior to its heat treatment can be applied to other saccharides than lactose as well.
  • the present invention provides a method of inhibiting isomerization of a reducing saccharide in an aqueous solution containing said reducing saccharide upon thermal treatment of said aqueous solution by acidifying the aqueous solution prior to and/or in the course of its thermal treatment.
  • the present invention provides a thermally treated aqueous solution containing at least one reducing saccharide.
  • the present invention provides the use of a thermally treated aqueous solution containing at least one reducing saccharide in a biotechnological production of a biological product.
  • the invention provides methods of producing a biological product, wherein a thermally treated aqueous solution containing at least one reducing saccharide is employed.
  • the invention provides a biological product produced by biotechnological production utilizing a thermally treated aqueous solution containing at least one reducing saccharide.
  • the invention provides the use of the biological product produced by biotechnological production utilizing a thermally treated aqueous solution containing at least one reducing saccharide for manufacturing a formulation.
  • the invention provides a formulation comprising a biological product that has been produced by a biotechnological production utilizing a thermally treated aqueous solution containing at least one reducing saccharide.
  • a method of inhibiting isomerization of a reducing saccharide in an aqueous solution containing said reducing saccharide (aqueous saccharide solution) upon thermal treatment of said aqueous saccharide solution comprising the step of acidifying the aqueous saccharide solution prior to and/or in the course of its thermal treatment.
  • reducing saccharide refers to any sugar or saccharide that is capable of acting as a reducing agent because it has a free aldehyde group.
  • the reducing saccharide comprises monosaccharides, disaccharides and oligosaccharides. All monosaccharides are reducing sugars, they can be classified into aldoses, which have an aldehyde group, and the ketoses, which have a ketone group. Ketoses must first tautomerize to aldoses before they can act as reducing sugars. Disaccharides are formed from two monosaccharide residues and oligosaccharides are formed from three to seven monosaccharide residues.
  • Disaccharides and oligosaccharides can be classified as either reducing or nonreducing. Reducing disaccharides like lactose and maltose have only one of their two anomeric carbons involved in the glycosidic bond, meaning that they can convert to an open-chain form with an aldehyde group.
  • the reducing saccharide is selected from the group consisting of aldoses, disaccharides and oligosaccharides.
  • aldose refers to monosaccharides that contain only one aldehyde group per molecule.
  • aldoses are D-(+)-glyceraldehyde, D-(-)-erythrose, D-(-)-threose, D-(-)-ribose, D-(-)-arabinose, D-(+)-xylose, D-(-)-lyxose, D-(+)-allose, D-(+)-altrose, D-(+)-glucose, D-(+)-mannose, D-(-)-gulose, D-(-)-idose, D-(+)-galactose, and D-(+)-talose.
  • the disaccharide is selected from the group consisting of lactose, maltose, trehalose, cellobiose, chitobiose, kojibiose, nigerose, isomaltose, sophorose, laminaribiose, gentibiose, turanose, matulose, palatinose, gentibiose, mannobiose, melibiose, melibiulose, rutinose, rutinulose and xylobiose.
  • oligosaccharide refers to saccharides consisting of 3, 4, 5, 6, or 7 monosaccharide residues, and thus comprises trisaccharides, tetrasaccharides, pentasaccharides, hexasaccharides and heptasaccharides.
  • an amount of the reducing saccharide is dissolved in a supply of water.
  • the water is distilled water, double distilled water or deionized water. Dissolution of the reducing saccharide in the water can be facilitated by stirring the water while the reducing saccharide is added or by mixing or shaking the water after the reducing saccharide had been added to the supply of water.
  • the aqueous saccharide solution is acidified to a pH having a value of between about 1 to about 6, preferably to a pH having a value of between about 2 to about 5, and more preferably to a pH having a value of between about 3 and about 4.
  • a pH of the aqueous saccharide solution having a value of between about 3 to about 5 was found to be of particular advantage, because isomerization of the reducing saccharide is inhibited or even prevented while formation of degradation products of said reducing saccharide is negligible.
  • the aqueous saccharide solution is acidified by adding an acid to the aqueous saccharide solution.
  • the acid can be any acid which does not lead to an undesired chemical reaction with the reducing saccharide.
  • An example of such an undesired chemical reaction is the formation of mucic acid if nitric acid is added to an aqueous lactose solution.
  • the acid can be selected from the group of organic acids and inorganic acids, with the provision that the inorganic acid is not nitric acid (or nitrous acid) if the reducing saccharide is galactose or a galactose-containing saccharide, as nitric acid oxidation of galactose or galactose-containing compounds such as lactose leads to mucic acid.
  • the at least one acid for acidifying the aqueous saccharide solution is an inorganic acid or mineral acid.
  • the inorganic acid is a suitable inorganic acid which - at the amount to be added to the aqueous saccharide solutions - does not inadvertently react with the saccharide. For example, adding nitric acid to an aqueous lactose solution may lead to mucic acid.
  • the inorganic acid is preferably selected from the group consisting of hydrochloric acid, sulfuric acid, sulfurous acid, phosphoric acid, boric acid, hydrofluoric acid, hydrobromic acid, perchloric acid, hydroiodic acid, and carbonic acid.
  • the aqueous saccharide solution can be acidified in that the aqueous saccharide solution is gassed with carbon dioxide in a pressurized container.
  • the at least one acid for acidifying the aqueous saccharide solution is an organic acid.
  • the organic acid may be selected from the group consisting of monocarboxylic acids, dicarboxylic acids, and tricarboxylic acids.
  • the monocarboxylic acid is selected from, but not limited to, the group consisting of carbonic acid, formic acid (methanoic acid), acetic acid (ethanoic acid), proprionic acid (propanoic acid), butyric acid (butanoic acid), and valeric acid (pentanoic acid).
  • the dicarboxylic acid is selected from the group consisting of oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, maleic acid, malic acid, fumaric acid, glutaconic acid, muconic acid, and citraconic acid.
  • the tricarboxylic acid is selected from the group consisting of citric acid, isocitric acid, and aconitic acid.
  • Adjusting the pH of the saccharide solution to an acidic value permits a thermal treatment of the reducing saccharide in the aqueous solution without or at least with a reduced isomerization of the reducing saccharide.
  • thermal treatment encompasses warming or heating and/or keeping the aqueous saccharide solution at an elevated temperature, i.e. a temperature above room temperature (21 °C).
  • Thermal treatment of the aqueous saccharide solution comprises heating the aqueous saccharide solution after acidification and/or while acidifying to a temperature of about 30 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C or even about 80 °C, and also includes keeping the aqueous saccharide solution at such a temperature - optionally after it has been heated to even higher temperatures - for an extended period of time, i.e. for several hours or even days, such as - for example, but not limited thereto - for about 20 hours, about 30 hours, about 40 hours, about 50 hours, about 60 hours, about 72 hours or even longer.
  • Heating and/or keeping an aqueous solution containing a reducing saccharide at such elevated temperatures without isomerization or with significantly reduced isomerization of the reducing saccharide provides multiple advantages such as - for example - the option of dissolving a higher amount of the saccharide in a given amount of water thereby increasing the saccharide concentration in the aqueous solution and reducing the volume of an aqueous saccharide solution to be supplied to a batch for obtaining a desired final saccharide concentration.
  • the viscosity of the aqueous saccharide solution can be decreased by heating/keeping the aqueous saccharide solution at an elevated temperature, thereby facilitating handling and/or pumping of the aqueous saccharide solution, e.g. through a membrane filter.
  • thermal treatment also encompasses heating and/or keeping the aqueous saccharide solution for some time at an elevated temperature which is suitable for sterilizing the aqueous saccharide solution.
  • thermal treatment also comprises heating the aqueous saccharide solution to a temperature in the range of about, but not limited to, 115 °C to 150 °C and keeping the temperature for up to about 60 minutes.
  • the aqueous saccharide solution is sterilized by autoclaving.
  • Autoclaving is one of the most important methods of germ destruction wherein saturated, superheated steam is utilized. The condensation of steam on the object to be sterilized releases energy which causes irreversible damage to the microorganisms.
  • the interior of the autoclave is vented during the intial rise time. In doing so, the atmospheric air is displaced from the interior and replaced by saturated, superheated steam. Venting takes place using a flow process or through fractioned venting; once venting is complete, the vent valve is closed. This marks the start of the compensation time.
  • Every point of the item to be sterilised reaches the required temperature due to the effect of the saturated steam. After this, the actual sterilisation phase begins.
  • the duration of sterilisation is dependent on both germ loading and sterilisation temperature.
  • Autoclaving at 121.1 °C (250 °F) for 15 minutes to 30 minutes is seen as standard. Vegetative forms, encompassing procaryotic and eucaryotic organisms as well as viruses/bacteriophages, can usually be inactivated within a few minutes at temperatures of 65 °C - 100 °C whereas survival forms such as spores may have to be treated at temperatures up to 140 °C. Prions require at least 30 minutes at 132 °C to 134 °C and 3 bar pressure in order to be inactivated or destroyed.
  • the subsequent cool-down phase, and thus the end of the autoclave cycle starts after the sterilisation time.
  • the aqueous saccharide solution is sterilized by a process called "ultra-high-temperature treatment", a continuous sterilization method, which comprises heating the aqueous to a temperature of 130 °C - 150 °C with 140 °C as a main point.
  • the corresponding holding time may vary from 8 to 40 seconds, occasionally to up to 5 minutes, depending on the properties of the solution to be sterilized.
  • the aqueous saccharide solution is subjected to a high temperature/short time (HTST) pasteurization, in which the solution is heated to a temperature of between 71.5 °C to 74 °C, preferably to 72 °C for about 15 seconds to about 30 seconds, and is moved in a controlled, continuous flow while subjected to said thermal treatment.
  • HTST high temperature/short time
  • the aqueous saccharide solution is subjected to "flash pasteurization", wherein the aqueous saccharide solution is subjected to 71.7 °C for 15 seconds.
  • Acidifying an aqueous solution of a reducing saccharide prior to subjecting the aqueous saccharide solution to any of these thermal treatments and/or in the course of its thermal treatment for sterilizing the aqueous saccharide solution inhibits or even prevents isomerization of the reducing saccharide in the aqueous solution upon its heat treatment.
  • a thermally treated aqueous solution containing at least one reducing saccharide which is obtained by the method according to the first aspect, i.e. by a method of inhibiting isomerization of said reducing saccharide in an aqueous solution of said reducing saccharide, including the acidification of the aqueous saccharide solution prior to and/or in the course of a thermal treatment of said aqueous saccharide solution.
  • the thermally treated aqueous solution containing at least one reducing saccharide which is obtained by the acidification of the aqueous saccharide solution prior to and/or in the course of its thermal treatment and which contains no or at least less amounts of undesired isomerization products of said at least one reducing saccharide as compared to a similar aqueous solution of the same reducing saccharide which was not acidified prior to an identical thermal treatment.
  • the aqueous solution containing a reducing saccharide is a sterile aqueous solution.
  • the sterile aqueous solution containing a reducing saccharide is obtained by the method of inhibiting isomerization of said reducing saccharide as described herein before, including the thermal treatment of said aqueous saccharide solution for sterilizing said aqueous saccharide solution.
  • aqueous solution has been sterilized by the thermal treatment.
  • the aqueous solution containing a reducing saccharide has an elevated temperature, i.e. a temperature of about 30 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C or even about 80 °C, and contains the reducing saccharide in an amount that is higher than the amount of said reducing saccharide that can be dissolved in water at room temperature.
  • an aqueous solution containing lactose in a concentration of ⁇ 10 mM, preferably in a concentration of ⁇ 100 mM, more preferably in a concentration of ⁇ 0.66 M, most preferably in a concentration of of ⁇ 1 M, is provided if the temperature of the acidified aqueous lactose solution is maintained at about 40 °C to about 60 °C.
  • the aqueous saccharide solution containing at least one reducing saccharide, such as - for example - lactose, in an amount that is higher than the amount of the saccharide that can be dissolved in water at room temperature may be a sterile aqueous lactose solution that has been sterilized by means of a thermal treatment for sterilization as described herein before and allowed to cool down to the desired elevated temperature at which the sterile aqueous saccharide solution is kept.
  • the invention provides the use of a thermally treated aqueous solution containing a reducing saccharide as described herein before in a biotechnological production of a biological product.
  • the use of the thermally treated aqueous solution containing a reducing saccharide in a biotechnological production of a biological product comprises the use in a biocatalytic production process.
  • biocatalytic production process as used herein is understood to refer to a process for producing a biological product wherein one or more purified or isolated enzymes are contacted with one or more educts in an in vitro reaction to convert the one or more educts to the desired biological product.
  • the use of the thermally treated aqueous solution containing a reducing saccharide comprises the use in a fermentative production process.
  • fermentative production process refers to a process wherein microorganisms are grown in a medium or broth with the aim of producing a biological product or specialty product that is synthesized by the microorganisms.
  • a thermally treated aqueous solution containing at least one reducing saccharide wherein the aqueous saccharide solution has been acidified as described herein before prior to and/or in the course of the thermal treatment of the aqueous saccharide solution is advantageous, among others, in that no or less undesired isomerization products of the reducing saccharide are present in the aqueous saccharide solution, and that no or less undesired isomerization products are supplied to the biotechnological production process as compared to a similar aqueous saccharide solution that was not acidified prior to its thermal treatment.
  • the invention provides methods for biotechnological production of a biological product.
  • the method is a biocatalytic production process.
  • the method comprises the steps of
  • the at least one reducing saccharide of the aqueous saccharide solution represents an educt of the biocatalytic production process.
  • the method is a fermentative production process.
  • “Fermentation” or “fermentative” refers to the bulk growth of microorganisms on or in a growth medium (fermentation broth) with the goal of producing a specific chemical product, the "biological product”.
  • a growth medium Fermentation broth
  • cells of one or a limited number of strains of microorganisms are grown in a bioreactor (fermenter) under optimum conditions for the microorganisms to perform the desired production with limited production of undesired impurities.
  • the environmental conditions inside the bioreactor such as temperature, nutrient concentrations, pH, and dissolved gases (especially oxygen for aerobic fermentations) affect the growth and productivity of the organisms, and are therefore monitored, controlled and adjusted if necessary.
  • the method of fermentative production of a biological product comprises the steps of:
  • said living cell is a prokaryotic cell or a eukaryotic dell.
  • Appropriate cells include yeast, bacteria, archaebacteria, fungi, insect cells, plant cells and animal cells, including mammalian cells (such as human cells and cell lines).
  • the prokaryotic cell is a bacterial cell, preferably selected from the genus selected from the group consisting of Bacillus, Lactobacillus, Lactococcus, Enterococcus, Bifidobacterium, Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp ., and Pseudomonas.
  • Suitable bacterial species are Bacillus subtilis , Bacillus licheniformis , Bacillus coagulans, Bacillus thermophilus, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, Bacillus circulans, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium bifidum, Citrobacter freundii, Clostridium cellulolyticum, Clostridium Ijungdahlii, Clostridium autoethanogenum, Clostridium acetobutylicum, Corynebacterium glutamicum, Enterococcus faecium, Enterococcus thermophiles, Escherichia coli, Erwinia herbicola ( Pantoea agglomerans ), Lactobacillus acidophilus, Lactobacillus salivarius, Lactobac
  • the eukaryotic cell is a yeast cell, an insect cell, a plant cell or a mammalian cell.
  • the yeast cell is preferably selected from the group consisting of Saccharomyces sp. , in particular Saccharomyces cerevisiae , Saccharomycopsis sp., Pichia sp., in particular Pichia pastoris, Hansenula sp., Kluyveromyces sp., Yarrowia sp., Rhodotorula sp., and Schizosaccharomyces sp.
  • said biological product is a human milk oligosaccharide.
  • the human milk oligosaccharide may be selected from the group consisting of 2'-fucosyllactose, 3-fucosyllactose, 2',3-difucosyllactose, lacto- N -triose II, lacto- N -tetraose, lacto- N -neotetraose, lacto- N -fucopentaose I, lacto- N- neofucopentaose I, lacto- N -fucopentaose II, lacto- N -fucopentaose III, lacto- N- fucopentaose V, lacto- N -neofucopentaose V, lacto- N -difucohexaose I, lacto- N- N-
  • said reducing saccharide is lactose.
  • lactose has to be supplied to the fermentation broth for the living cells for producing the desired human milk oligosaccharide.
  • Being able to reduce or avoid the formation of lactulose upon heat sterilization of an aqueous lactose solution by the method according to the first aspect eliminates the need of removing lactulose from the HMO preparation when the HMO preparation shall be used for manufacturing a nutritional formula, especially an infant formula, a medicinal food or a dietary supplement.
  • a thermally treated aqueous saccharide solution containing at least one reducing saccharide wherein the aqueous saccharide solution has been acidified as described herein before prior to and/or in the course of its thermal treatment in a fermentative production process provides additional advantages.
  • the present invention permits sterilization of an aqueous solution containing a reducing saccharide by heat sterilization methods without or with reduced isomerization of the reducing saccharide.
  • aqueous solutions containing a reducing saccharide do not have to be sterilized by sterile filtration, which is less reliable than heat sterilization (e.g.
  • the present invention permits providing aqueous saccharide solutions containing at least one reducing saccharide, wherein the concentrations of the at least one reducing saccharide is higher than the saturation concentration of the at least one reducing saccharide at room temperature, as the aqueous saccharide solution can be heated and kept at an elevated temperature, i.e. a temperature above room temperature.
  • an aqueous saccharide solution at an elevated temperature reduces the viscosity of the aqueous saccharide solution which in turn eases handling of the aqueous saccharide solution, for example when pumping the aqueous saccharide solution through a pipe or a hose.
  • being able to provide an aqueous saccharide solution having an increased saccharide concentration permits obtaining higher product yields in a fermentative production process.
  • a higher saccharide concentration in the fermentation broth in a given fermenter can be achieved or a predetermined saccharide concentration can be maintained for a longer time period as the volume in the fermenter being available for supplies is depleted more slowly.
  • This provides more of the reducing saccharide to the cells for producing the desired biological product, and hence increases the yield of the desired biological product that can be obtained in a single batch fermentation.
  • the desired biological product can be produced - at the end of the fermentation process - in an amount of ⁇ 100 g/L in the fermentation broth, preferably in an amount of ⁇ 150 g/L in the fermentation broth, more preferably in an amount of ⁇ 200 g/L in the fermentation broth.
  • amounts of 2'-fucosyllactose of more than 100 g/L, namely of about 150 g/L were obtained when a acidified 0.66 M aqueous lactose solution was used which was heat sterilized, and even higher yields can be obtained if the lactose concentration in the aqueous solution to be fed to the fermentation broth is further increased.
  • the at least one reducing saccharide is lactose
  • said biological product is selected from the group consisting of lactosucrose and lactobionic acid.
  • the invention provides a biological product which has been produced by one of the methods according to the fourth aspect.
  • the biological product is a human milk oligosaccharide, preferably a human milk oligosaccharide selected from the group consisting of 2'-fucosyllactose, 3-fucosyllactose, 2',3-difucosyllactose, lacto- N -triose II, lacto- N- tetraose, lacto- N -neotetraose, lacto- N -fucopentaose I, lacto- N -neofucopentaose I, lacto- N -fucopentaose II, lacto- N -fucopentaose III, lacto- N -fucopentaose V, lacto- N- neofucopentaose V, lacto- N -difucohexaose I, lacto- N -difucosylhexaose II, para
  • the biological product is selected from the group consisting of lactosucrose and lactobionic acid or derivatives of the above mentioned human milk oligosaccharides.
  • the invention provides the use of the biological product for manufacturing a formulation.
  • the biological product is a human milk oligosaccharide, selected from the group consisting of 2'-fucosyllactose, 3-fucosyllactose, 2',3-difucosyllactose, lacto- N -triose II, lacto- N -tetraose, lacto- N - neo tetraose, lacto- N -fucopentaose I, lacto- N -neofucopentaose I, lacto- N -fucopentaose II, lacto- N -fucopentaose III, lacto- N -fucopentaose V, lacto- N - neo fucopentaose V, lacto- N -difucohexaose I, lacto- N- difucosylhexaose II
  • the method of inhibiting isomerization may provide a heat sterilized lactose solution without or with reduced amounts of lactulose for fermentative production of a human milk oligosaccharide.
  • Said human milk oligosaccharide may then be employed in the manufacturing of a nutritional formulation, preferably an infant formula, which does not contain or contains less amount of epilactose, lactulose and/or a derivative of lactulose such as fucosyllactulose (without the need of removing lactulose or its derivative from the HMO preparation).
  • formulations comprising at least one biological product that has been produced by a biotechnological production process as described herein before.
  • Said formulation is preferably selected from the group consisting of nutritional formulations, preferably infant formula, medicinal food and dietary supplements.
  • an element described herein of an apparatus embodiment is an example of a means for carrying out the function performed by the element for the purpose of carrying out the invention.
  • a 0.66 M lactose solution was prepared by dissolving 226 g of lactose in water. The final volume of the solution was 1 litre. At a temperature of 30°C to 35°C the pH was adjusted by using 50 % (w/v) citrate or 99 % (v/v) acetic acid. Afterwards, the solution was sterilized in a vertical autoclave (Systec VX-65, Linden, Germany) at 121°C for 20 minutes. Samples were taken before and after heat sterilization and kept frozen prior to analysis by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • HPLC HPLC was carried out using a RID-10A refractive index detector (Shimadzu, Germany) and a Waters XBridge Amide Column 3.5 ⁇ m (250 x 4.6 mm) (Eschborn, Germany) connected to a Shimadzu HPLC system. Isocratic elution was carried out with 30% solvent A (50% (v/v) acetonitrile in double distilled water, 0.1 % (v/v) NH4OH) and 70% solvent B (80% (v/v) acetonitrile in double distilled water, 0.1% (v/v) NH4OH) at 35°C and at a flow rate of 1.4 mL min-1.
  • solvent A 50% (v/v) acetonitrile in double distilled water, 0.1 % (v/v) NH4OH
  • solvent B 80% (v/v) acetonitrile in double distilled water, 0.1% (v/v) NH4OH
  • Table 1 Relative amount of sugars detected in pH adjusted 0.66 M lactose solutions before and after heat sterilization. The pH adjustment was carried out using 50 % (w/v) citrate. Depicted is the percental amount of sugars (area under the curve; AUC) detected by HPLC.
  • pH Relative composition [%] Monosaccharides Lactulose Lactose before heat sterilization 3.0 - 6.8 n. d. n. d. 100 after heat sterilization 6.8 (no pH adjustment) 0.44 6.16 93.40 5.0 0.27 0.87 98.85 4.5 n. d. 0.15 99.85 4.0 0.68 n. d. 99.32 3.5 1.87 n. d. 98.13 3.0 5.96 n.
  • a 0.66 M lactose solution was prepared by dissolving 226 g of lactose in water. The final volume of the solution was 1 litre. At a temperature of 30 °C to 35 °C the pH was adjusted by using 37 % (v/v) hydrochloric acid, 50 % (v/v) phosphoric acid or 96 % (v/v) sulfuric acid. Afterwards, the solution was sterilized in a vertical autoclave (Systec VX-65, Linden, Germany) at 121 °C for 20 minutes. Samples were taken before and after heat sterilization and kept frozen prior to analysis by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • HPLC HPLC was carried out using a RID-10A refractive index detector (Shimadzu, Germany) and a Waters XBridge Amide Column 3.5 ⁇ m (250 x 4.6 mm) (Eschborn, Germany) connected to a Shimadzu HPLC system. Isocratic elution was carried out with 30% solvent A (50% (v/v) acetonitrile in double distilled water, 0.1 % (v/v) NH4OH) and 70% solvent B (80% (v/v) acetonitrile in double distilled water, 0.1% (v/v) NH4OH) at 35°C and at a flow rate of 1.4 mL min-1.
  • solvent A 50% (v/v) acetonitrile in double distilled water, 0.1 % (v/v) NH4OH
  • solvent B 80% (v/v) acetonitrile in double distilled water, 0.1% (v/v) NH4OH
  • Table 3 Relative amount of sugars detected in pH adjusted 0.66 M lactose solutions before and after heat sterilization. The pH adjustment was carried out using 37 % (v/v) hydrochloric acid. Depicted is the percental amount of sugars (area under the curve; AUC) detected by HPLC.
  • pH Relative composition [%] Monosaccharides Lactulose Lactose before heat sterilization 3.0-6.8 n. d. n. d. 100 after heat sterilization 6.8 (no pH adjustment) 0.44 6.16 93.40 5.0 n. d. 0.57 99.43 4.5 n. d. 0.17 99.83 4.0 n. d. 0.20 99.80 3.5 1.50 n. d.
  • E. coli BL21 (DE3) ⁇ nagAb ⁇ wcaJ ⁇ fuclK ⁇ pfkA strain was used in accordance with European patent application 16 196 486 , overexpressing enzymes for de novo synthesis of GDP-Fucose (ManB, ManC, Gmd, WcaG), the bifunctional L-fucokinase/L-fucose 1-phosphat guanylyltranferase of Bacteroides fragilis , the 2-fucosyltransferase gene wbgL from E .
  • coli :O126 the lactose permease gene lacY , the sugar efflux transporter yberc0001_ 9420 from Yersinia bercovieri ATCC 43970, the fructose-1,6-bisphosphate aldolase ( fbaB ) and a heterologous fructose-1,6-bisphosphate phosphatase ( fbpase ) from Pisum sativum.
  • the E . coli strain was cultivated in a 3L fermenter at 33°C in a mineral salts medium that contains 3 g/L KH 2 PO 4 , 12 g/L K 2 HPO 4 , 5 g/L (NH 4 ) 2 SO 4 , 0.3 g/L citric acid, 2 g/L MgSO 4 ⁇ 7H 2 O, 0.1 g/L NaCl and 0.015 g/L CaCl 2 ⁇ 6H 2 O with 1 mL/L trace element solution (54.4 g/L ammonium ferric citrate, 9.8 g/L MnCl 2 ⁇ 4H 2 O, 1.6 g/L CoCl 2 ⁇ 6H 2 O, 1 g/L CuCl 2 ⁇ 2H 2 O, 1.9 g/L H 3 BO 3 , 9 g/L ZnSO 4 ⁇ 7H 2 O, 1.1 g/L Na 2 MoO 4 ⁇ 2H 2 O, 1.5 g/L Na 2 SeO 3
  • the pH was hold at 7.0 by titrating 25% ammonia.
  • the fermenter was inoculated to an OD 600 of 0.1 with a pre-culture grown in the described medium but lacking lactose.
  • the glycerol feed (60% v/v) as well as the 0.66 M lactose feed (acidified to pH 3.0 using 96 %(v/v) sulfuric acid prior to heat sterilization) was started.
  • a concentration of 10-40 mM lactose was held throughout the production phase of the fermentation process, regulated according to HPLC-analyses.
  • Glycerol (60% v/v) was fed with flow rates of 6-8 ml/L/h (referring to the starting volume). The fermentation was stopped when the filling volume in the tank reached its maximum. At this point, a 2'-fucosyllactose titer of 146 g/L was determined in the culture supernatant of the broth.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Beans For Foods Or Fodder (AREA)
EP17161671.7A 2017-03-17 2017-03-17 Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung Active EP3375291B1 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP17161671.7A EP3375291B1 (de) 2017-03-17 2017-03-17 Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung
ES17161671T ES2928859T3 (es) 2017-03-17 2017-03-17 Un método para inhibir la isomerización de un sacárido reductor tras el tratamiento térmico
DK17161671.7T DK3375291T3 (da) 2017-03-17 2017-03-17 Fremgangsmåde til hæmning af isomerisering af et reducerende saccharid efter termisk behandling
PL17161671.7T PL3375291T3 (pl) 2017-03-17 2017-03-17 Sposób hamowania izomeryzacji sacharydu redukującego po obróbce termicznej
JP2019550677A JP7186175B2 (ja) 2017-03-17 2018-03-16 熱処理による還元糖の異性化を抑制する方法
EP18710075.5A EP3595455A1 (de) 2017-03-17 2018-03-16 Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung
SG11201906991PA SG11201906991PA (en) 2017-03-17 2018-03-16 A method of inhibiting isomerization of a reducing saccharide upon thermal treatment
PCT/EP2018/056727 WO2018167293A1 (en) 2017-03-17 2018-03-16 A method of inhibiting isomerization of a reducing saccharide upon thermal treatment
MX2019010872A MX2019010872A (es) 2017-03-17 2018-03-16 Un metodo de inhibicion de isomerizacion de un sacarido reductor en el tratamiento termico.
CN201880018599.8A CN110418577A (zh) 2017-03-17 2018-03-16 一种在热处理时抑制还原糖异构化的方法
RU2019131462A RU2797427C2 (ru) 2017-03-17 2018-03-16 Способ ингибирования изомеризации восстанавливающего сахарида при тепловой обработке
US16/493,996 US20200087690A1 (en) 2017-03-17 2018-03-16 A method of inhibiting isomerization of a reducing saccharide upon thermal treatment
BR112019017840A BR112019017840A8 (pt) 2017-03-17 2018-03-16 Método de inibir a isomerização de um sacarídeo redutor mediante tratamento térmico e uso de uma solução aquosa estéril
KR1020197023924A KR20190130125A (ko) 2017-03-17 2018-03-16 열 처리시에 환원 당류의 이성체화를 저해하는 방법
AU2018235156A AU2018235156B2 (en) 2017-03-17 2018-03-16 A method of inhibiting isomerization of a reducing saccharide upon thermal treatment
PH12019550151A PH12019550151A1 (en) 2017-03-17 2019-08-13 A method of inhibiting isomerization of a reducing saccharide upon thermal treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17161671.7A EP3375291B1 (de) 2017-03-17 2017-03-17 Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung

Publications (2)

Publication Number Publication Date
EP3375291A1 true EP3375291A1 (de) 2018-09-19
EP3375291B1 EP3375291B1 (de) 2022-08-10

Family

ID=58448315

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17161671.7A Active EP3375291B1 (de) 2017-03-17 2017-03-17 Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung
EP18710075.5A Pending EP3595455A1 (de) 2017-03-17 2018-03-16 Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18710075.5A Pending EP3595455A1 (de) 2017-03-17 2018-03-16 Verfahren zur hemmung der isomerisierung eines reduzierenden saccharids nach thermischer behandlung

Country Status (14)

Country Link
US (1) US20200087690A1 (de)
EP (2) EP3375291B1 (de)
JP (1) JP7186175B2 (de)
KR (1) KR20190130125A (de)
CN (1) CN110418577A (de)
AU (1) AU2018235156B2 (de)
BR (1) BR112019017840A8 (de)
DK (1) DK3375291T3 (de)
ES (1) ES2928859T3 (de)
MX (1) MX2019010872A (de)
PH (1) PH12019550151A1 (de)
PL (1) PL3375291T3 (de)
SG (1) SG11201906991PA (de)
WO (1) WO2018167293A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020120426A1 (en) * 2018-12-14 2020-06-18 Société des Produits Nestlé S.A. Stable aqueous composition comprising oligosaccharides
WO2023083977A1 (en) * 2021-11-11 2023-05-19 Dsm Ip Assets B.V. Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s))
RU2819341C2 (ru) * 2018-12-14 2024-05-17 Сосьете Де Продюи Нестле С.А. Водная композиция, содержащая олигосахариды грудного молока со звеном глюкозы на восстанавливающем конце, её применение в качестве обогатителя молока для младенцев и способ предотвращения изомеризации в водных композициях во время термической обработки олигосахаридов грудного молока со звеном глюкозы на восстанавливающем конце

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210117292A (ko) * 2019-01-16 2021-09-28 글리콤 에이/에스 무정형 시알릴화 올리고당

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB423063A (en) * 1933-12-06 1935-01-24 Ninni Maria Kronberg Improvements relating to the manufacture of milk powder
US2826502A (en) * 1955-04-28 1958-03-11 Nat Dairy Prod Corp Conversion of lactose to glucose and galactose with a minimum production of oligosaccharides
EP0349712A1 (de) * 1988-04-11 1990-01-10 Biodyn AG Nahrungsmittel oder Getränk
WO2015032413A1 (en) * 2013-09-06 2015-03-12 Glycom A/S Fermentative production of oligosaccharides
WO2015150328A1 (en) * 2014-03-31 2015-10-08 Jennewein Biotechnologie Gmbh Total fermentation of oligosaccharides
US20160376616A1 (en) * 2014-03-13 2016-12-29 Mitsubishi Chemical Corporation Treatment method of saccharide solution, production method of treated saccharide solution, treated saccharide solution, production method of organic compound and culture method of microorganism
EP3315610A1 (de) 2016-10-29 2018-05-02 Jennewein Biotechnologie GmbH Verbessertes verfahren zur herstellung von fucosylierten oligosacchariden

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1052210A (en) * 1911-03-07 1913-02-04 Charles De Bock Sterilizing apparatus.
JPS52122663A (en) * 1976-04-08 1977-10-15 Karupisu Shiyokuhin Kougiyou K Method of producing strainght sour mild drink
US6171633B1 (en) * 1998-08-14 2001-01-09 Natura, Inc. Milk-based drink
WO2011032957A1 (de) * 2009-09-16 2011-03-24 Gea Mechanical Equipment Gmbh Verfahren zur herstellung von länger haltbarer frischmilch
CA2827313C (en) * 2011-02-16 2023-08-22 Glycosyn LLC Biosynthesis of human milk oligosaccharides in engineered bacteria
US9029136B2 (en) * 2012-07-25 2015-05-12 Glycosyn LLC Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
CN105683387B (zh) 2013-09-06 2020-02-21 格礼卡姆股份公司 寡糖的发酵生产
EP2845905B8 (de) 2013-09-10 2021-07-14 Chr. Hansen HMO GmbH Herstellung von Oligosacchariden
JP2017515455A (ja) * 2014-05-15 2017-06-15 グリコシン リミテッド ライアビリティー カンパニー フコシル化オリゴ糖の生産に使用するためのアルファ（１，２）フコシルトランスフェラーゼ・シンジーン
EP3191499A4 (de) * 2014-09-09 2018-06-06 Glycosyn LLC (alpha)1,3-fucosyltransferasen zur verwendung bei der herstellung von fucosylierten oligosacchariden

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB423063A (en) * 1933-12-06 1935-01-24 Ninni Maria Kronberg Improvements relating to the manufacture of milk powder
US2826502A (en) * 1955-04-28 1958-03-11 Nat Dairy Prod Corp Conversion of lactose to glucose and galactose with a minimum production of oligosaccharides
EP0349712A1 (de) * 1988-04-11 1990-01-10 Biodyn AG Nahrungsmittel oder Getränk
WO2015032413A1 (en) * 2013-09-06 2015-03-12 Glycom A/S Fermentative production of oligosaccharides
US20160376616A1 (en) * 2014-03-13 2016-12-29 Mitsubishi Chemical Corporation Treatment method of saccharide solution, production method of treated saccharide solution, treated saccharide solution, production method of organic compound and culture method of microorganism
WO2015150328A1 (en) * 2014-03-31 2015-10-08 Jennewein Biotechnologie Gmbh Total fermentation of oligosaccharides
EP3315610A1 (de) 2016-10-29 2018-05-02 Jennewein Biotechnologie GmbH Verbessertes verfahren zur herstellung von fucosylierten oligosacchariden

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAM VIVIJS ET AL: "Identification of Genes Required for Growth of Escherichia coli MG1655 at Moderately Low pH", FRONTIERS IN MICROBIOLOGY, vol. 7, 25 October 2016 (2016-10-25), XP055385108, DOI: 10.3389/fmicb.2016.01672 *
J. P. KASS, L. S. PALMER: "Browning of Autoclaved Milk Chemical Factors Involved", INDUSTRIAL AND ENGINEERING CHEMISTRY, vol. 32, no. 10, 1 October 1940 (1940-10-01), US , pages 1360 - 1366, XP055660544, ISSN: 0019-7866, DOI: 10.1021/ie50370a019
MONTILLA A ET AL: "Egg shell as catalyst of lactose isomerisation to lactulose", FOOD CHEMISTRY, ELSEVIER LTD, NL, vol. 90, no. 4, 1 May 2005 (2005-05-01), pages 883 - 890, XP027770276, ISSN: 0308-8146, [retrieved on 20050501] *
NOOSHKAM MAJID ET AL: "Microwave-assisted isomerisation of lactose to lactulose and Maillard conjugation of lactulose and lactose with whey proteins and peptides", FOOD CHEMISTRY, vol. 200, 31 December 2015 (2015-12-31), pages 1 - 9, XP029401249, ISSN: 0308-8146, DOI: 10.1016/J.FOODCHEM.2015.12.094 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020120426A1 (en) * 2018-12-14 2020-06-18 Société des Produits Nestlé S.A. Stable aqueous composition comprising oligosaccharides
RU2819341C2 (ru) * 2018-12-14 2024-05-17 Сосьете Де Продюи Нестле С.А. Водная композиция, содержащая олигосахариды грудного молока со звеном глюкозы на восстанавливающем конце, её применение в качестве обогатителя молока для младенцев и способ предотвращения изомеризации в водных композициях во время термической обработки олигосахаридов грудного молока со звеном глюкозы на восстанавливающем конце
WO2023083977A1 (en) * 2021-11-11 2023-05-19 Dsm Ip Assets B.V. Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s))

Also Published As

Publication number Publication date
RU2019131462A (ru) 2021-04-19
RU2019131462A3 (de) 2021-07-19
JP2020509769A (ja) 2020-04-02
DK3375291T3 (da) 2022-10-31
SG11201906991PA (en) 2019-09-27
KR20190130125A (ko) 2019-11-21
EP3375291B1 (de) 2022-08-10
ES2928859T3 (es) 2022-11-23
PL3375291T3 (pl) 2022-11-28
MX2019010872A (es) 2019-12-11
BR112019017840A8 (pt) 2023-04-18
CN110418577A (zh) 2019-11-05
EP3595455A1 (de) 2020-01-22
AU2018235156B2 (en) 2023-04-27
JP7186175B2 (ja) 2022-12-08
WO2018167293A1 (en) 2018-09-20
US20200087690A1 (en) 2020-03-19
BR112019017840A2 (pt) 2020-04-14
AU2018235156A1 (en) 2019-08-15
PH12019550151A1 (en) 2020-06-08

Similar Documents

Publication Publication Date Title
CA2945661C (en) Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides
KR102630559B1 (ko) 인간 모유 올리고당을 생산하기 위한 미생물
AU2018235156B2 (en) A method of inhibiting isomerization of a reducing saccharide upon thermal treatment
DK2240570T3 (en) Bacterial production ghost (BG) using beta-propiolactone (BLP) for final inactivation
CN109266709A (zh) 乳酸链球菌素生产工艺
KR102013010B1 (ko) 투라노스를 생산하는 균주 및 이의 용도
RU2797427C2 (ru) Способ ингибирования изомеризации восстанавливающего сахарида при тепловой обработке
WO2006125362A1 (fr) Milieu de culture, procede de preparation dudit milieu et procede de culture de nisine
JP2006333847A (ja) Ｌ−乳酸生産菌およびｌ−乳酸液製造方法
DE69533386T2 (de) DNS, die für ein rekombinantes Enzym zur Umwandlung von Maltose in Trehalose kodiert
RU2475535C1 (ru) Способ получения пробиотического препарата лактоамиловорина
AU2016288656B2 (en) Process for producing lactic acid or its salts from fermentation using thermotolerance bacillus bacteria
US11578091B2 (en) Process for the manufacture of maltosyl-isomaltooligosaccharides (MIMO)
JP4436635B2 (ja) バクテリオシンを産出する有用物質生産菌を利用した有用物質の製造方法
RU2205216C2 (ru) Штамм бактерий enterococcus faecium в-2240d - продуцент оптически чистой l(+)-молочной кислоты и промышленный способ получения l(+)-молочной кислоты или ее солей
KR102014732B1 (ko) 미생물의 사균화 방법
EP2796543B1 (de) Verfahren zum sterilisieren mikrobieller zellen unter verwendung eines nichtionischen tensides auf polyethylenglycolbasis
EP2729559B1 (de) Verfahren zur reduzierung der viskosität einer mikroorganismushaltigen suspension oder eines konzentrats
JP2016136890A (ja) 乳酸菌のインターロイキン１０産生誘導能の増強方法
Klewicka et al. In vitro fermentation of galactosyl derivatives of polyols by Lactobacillus strains
WO2010119956A1 (ja) 乳酸菌生残性向上剤及びそれを用いた保蔵方法
JPH10215865A (ja) β−１，３−グルカナーゼの製造方法
JPH02234667A (ja) ビフィズス菌の増殖促進剤とその製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190319

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200129

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CHR. HANSEN HMO GMBH

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602017060430

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A23C0007040000

Ipc: C12P0019000000

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/00 20160101ALI20220126BHEP

Ipc: A23L 29/30 20160101ALI20220126BHEP

Ipc: C13K 13/00 20060101ALI20220126BHEP

Ipc: C13K 7/00 20060101ALI20220126BHEP

Ipc: C13K 5/00 20060101ALI20220126BHEP

Ipc: C13B 50/00 20110101ALI20220126BHEP

Ipc: C07H 3/04 20060101ALI20220126BHEP

Ipc: A61K 31/7016 20060101ALI20220126BHEP

Ipc: A23C 9/156 20060101ALI20220126BHEP

Ipc: C07H 3/06 20060101ALI20220126BHEP

Ipc: C07H 1/04 20060101ALI20220126BHEP

Ipc: C07H 1/08 20060101ALI20220126BHEP

Ipc: A23C 9/20 20060101ALI20220126BHEP

Ipc: A23C 9/15 20060101ALI20220126BHEP

Ipc: A23C 9/154 20060101ALI20220126BHEP

Ipc: A23C 7/04 20060101ALI20220126BHEP

Ipc: A23L 33/21 20160101ALI20220126BHEP

Ipc: C12P 19/26 20060101ALI20220126BHEP

Ipc: C12P 19/18 20060101ALI20220126BHEP

Ipc: C12P 19/00 20060101AFI20220126BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220325

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1510574

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220815

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017060430

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20221026

Ref country code: NO

Ref legal event code: T2

Effective date: 20220810

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2928859

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20221123

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 40609

Country of ref document: SK

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221212

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221210

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602017060430

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

26 Opposition filed

Opponent name: GLYCOM A/S

Effective date: 20230510

Opponent name: FRIESLANDCAMPINA NEDERLAND B.V.

Effective date: 20230503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230414

Year of fee payment: 7

Ref country code: CH

Payment date: 20230402

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1510574

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230317

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240320

Year of fee payment: 8

Ref country code: IE

Payment date: 20240319

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240318

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20240319

Year of fee payment: 8

Ref country code: DE

Payment date: 20240321

Year of fee payment: 8

Ref country code: CZ

Payment date: 20240301

Year of fee payment: 8

Ref country code: BG

Payment date: 20240315

Year of fee payment: 8

Ref country code: GB

Payment date: 20240322

Year of fee payment: 8

Ref country code: SK

Payment date: 20240308

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240321

Year of fee payment: 8

Ref country code: PL

Payment date: 20240305

Year of fee payment: 8

Ref country code: NO

Payment date: 20240321

Year of fee payment: 8

Ref country code: IT

Payment date: 20240329

Year of fee payment: 8

Ref country code: FR

Payment date: 20240320

Year of fee payment: 8

Ref country code: DK

Payment date: 20240321

Year of fee payment: 8

Ref country code: BE

Payment date: 20240320

Year of fee payment: 8